Inflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysis
| dc.contributor.author | Gómez Gómez, Alejandro | |
| dc.contributor.author | García González, Javier | |
| dc.contributor.author | Peiteado, Diana | |
| dc.contributor.author | Borrego Sanz, Lara | |
| dc.contributor.author | Arriola Villalobos, Pedro | |
| dc.contributor.author | Esteban Ortega, María del Mar | |
| dc.contributor.author | Martín López, María | |
| dc.contributor.author | Ventura Hidalgo, María | |
| dc.contributor.author | Pérez Blázquez, Eugenio | |
| dc.contributor.author | Pato, Esperanza | |
| dc.contributor.author | Díaz Valle, David | |
| dc.contributor.author | Muñoz Fernández, Santiago | |
| dc.contributor.author | Rodríguez Rodríguez, Luis | |
| dc.date.accessioned | 2021-08-25T09:09:37Z | |
| dc.date.available | 2021-08-25T09:09:37Z | |
| dc.date.issued | 2021 | |
| dc.description.abstract | Purpose: To estimate the incidence rate (IR) and identify risk factors associated to inflammatory relapse after immunosuppressive drug (ISD) discontinuation in noninfectious uveitis patients. Methods: Multicenter longitudinal retrospective study, including patients from four uveitis clinics followed-up until December 2018. Hazard ratios for different variables were estimated using multivariable Cox models. Results: 32 patients (34 episodes of ISD discontinuation) were analyzed (median and maximum follow-up time: 2.4 and 19.2 years, respectively). Fourteen patients presented at least one relapse: anterior (8 patients), intermediate (5) and posterior (8). IR (95% confidence interval) of the first relapse was 14.3 (8.6–23.8) episodes per 100 patient-years (median survival time: 4.8 years). Early use of ISDs, panuveitis, and higher oral corticosteroid dosage at discontinuation were associated with higher hazards of relapse in multivariable analysis. Conclusions: Relapse is a frequent and early event after ISD discontinuation. Identifying relapse risk factors could support the physician’s decision regarding ISD discontinuation. | spa |
| dc.description.filiation | UEM | spa |
| dc.description.impact | 3.728 JCR (2021) Q2, 23/62 Ophthalmology | spa |
| dc.description.impact | 1,232 SJR (2021) Q1, 21/128 Ophthalmology | spa |
| dc.description.impact | No data IDR 2021 | spa |
| dc.description.sponsorship | Instituto de Salud Carlos III (ISCIII), Ministerio de Sanidad, Consumo y Bienestar Social (Contrato de investigación Miguel Servet: CPII17 / 00014 a LRR). | spa |
| dc.identifier.citation | Gómez-Gómez, A., García-González, J., Peiteado, D., Borrego-Sanz, L., Arriola-Villalobos, P., Esteban-Ortega, M., Martín-López, M., Ventura-Hidalgo, M., Pérez-Blázquez, E., Pato, E., Díaz-Valle, D., Muñoz-Fernández, S., & Rodríguez-Rodríguez, L. (2021). Inflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysis. Ocular Immunology and Inflammation, 29(2), 376-387. https://doi.org/10.1080/09273948.2019.1681469 | spa |
| dc.identifier.doi | 10.1080/09273948.2019.1681469 | |
| dc.identifier.issn | 0927-3948 | |
| dc.identifier.issn | 1744-5078 | |
| dc.identifier.uri | http://hdl.handle.net/11268/10314 | |
| dc.language.iso | eng | spa |
| dc.peerreviewed | Si | spa |
| dc.rights.accessRights | restricted access | spa |
| dc.subject.other | Uveítis | spa |
| dc.subject.other | Inmunosupresores | spa |
| dc.subject.unesco | Farmacología | spa |
| dc.subject.unesco | Inmunología | spa |
| dc.subject.unesco | Oftalmología | spa |
| dc.title | Inflammatory Relapses after Immunosuppressive Drug Discontinuation in Uveitis Patients: A Survival Analysis | spa |
| dc.type | journal article | spa |
| dspace.entity.type | Publication | |
| relation.isAuthorOfPublication | 0ae30c23-484f-4f13-9a4d-e399c2566789 | |
| relation.isAuthorOfPublication | af8b4da6-c0e8-459a-8f7f-8b365df94d3b | |
| relation.isAuthorOfPublication.latestForDiscovery | 0ae30c23-484f-4f13-9a4d-e399c2566789 |

